Northpond Ventures

QbDVision is a developer of a product life cycle management platform tailored for the biopharma sector. The platform offers a digital solution for managing development processes by consolidating data and knowledge from various teams into a single, searchable, cloud-based hub. It integrates product, process, and quality workflows, enhancing collaboration and minimizing inefficiencies associated with outdated software systems. This comprehensive approach allows organizations to maintain a historical perspective on their product and processes, facilitating better decision-making throughout the life cycle. Ultimately, QbDVision aims to increase the likelihood of technical success and expedite the delivery of therapeutic breakthroughs to patients.

Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.

EnPlusOne Biosciences specializes in developing innovative solutions for RNA therapeutics through its advanced synthesis platform. The company focuses on enzymatic-based RNA synthesis, which aims to address the limitations of traditional chemical synthesis methods. By tackling systemic challenges related to scaled production and access to novel therapeutic modifications, EnPlusOne enables the sustainable manufacturing of therapeutic RNA at a commercial scale. This approach positions the company to contribute significantly to the growing field of RNA-based therapeutics.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

VieCure is a provider of an advanced artificial intelligence platform designed to enhance cancer care by transforming data into actionable insights. The platform enables oncologists to develop personalized treatment plans that are tailored to each patient's unique needs, drawing on the latest evidence-based knowledge and genomic guidelines. By codifying premier cancer information, VieCure supports clinicians in creating comprehensive care strategies that align with nationally accepted standards. This innovative approach not only aids healthcare professionals in delivering high-quality care but also empowers patients to actively engage in their treatment journey, ultimately helping them to live their best lives.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Established in 2019 and headquartered in Waltham, Massachusetts, Eleanor Health offers comprehensive, whole-person care for mental health and substance misuse. Its services include evidence-based outpatient care, medication-assisted treatment for addiction, and personalized recovery plans, which are delivered through a network of outpatient clinics, virtually, and in community and home settings. This integrated approach aims to expedite the recovery process for individuals suffering from substance use disorders.

Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.

Totus Medicines specializes in developing innovative therapies to address previously untreatable diseases by harnessing advanced chemical biology techniques. The company utilizes a proprietary platform that enables high-throughput drug discovery, allowing it to screen billions of drug candidates against thousands of biological targets. This approach focuses on identifying effective molecules for traditionally challenging and undruggable targets, including those associated with cancer, Alzheimer's, infectious diseases, and the aging process. By converting genetic insights into viable therapeutic options, Totus Medicines aims to make a significant impact on the treatment landscape for various complex diseases.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that connect diagnosis and treatment through a comprehensive ecosystem of devices, software, and services. By empowering patients to monitor their health and manage diseases, Vital Bio aims to enhance the overall healthcare experience. Their approach seeks to reduce disparities in healthcare outcomes and redistribute control to patients while equipping healthcare providers with the tools necessary to achieve better results.

Telesis Bio is a biotech company established in 2013 and headquartered in San Diego, USA. It specializes in synthetic biology, providing researchers with tools to design, code, and create synthetic DNA and mRNA. The company focuses on enabling the rapid, accurate, and reproducible construction of high-quality synthetic genetic material for various applications in synthetic biology. Telesis Bio manufactures and sells laboratory equipment, including synthetic biology instruments, reagents, and related products. Its product offerings include the BioXp system, BioXp kits, benchtop reagents, and BioXp biofoundry services, all aimed at supporting researchers in their scientific endeavors.

SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.

Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.

Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

Perceiv AI is a healthcare company focused on precision medicine, utilizing advanced artificial intelligence to enhance patient outcomes. The company specializes in identifying suitable subjects for clinical trials, helping pharmaceutical firms improve their chances of success by analyzing complex data related to heterogeneous diseases. Perceiv's platform integrates various types of longitudinal data, including imaging, genetic, phenotypic, and clinical variables, to characterize individuals more accurately. This approach enables healthcare organizations to target individuals at risk of disease progression, particularly in areas such as age-related conditions, including Alzheimer's disease and cardiovascular issues. Through its innovative AI-driven solutions, Perceiv aims to facilitate the development of effective therapies and improve the efficacy of clinical trials.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and farm revenues while addressing challenges such as drought. The company offers Source, a solution that enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby helping growers optimize crop performance sustainably. Additionally, Sound Agriculture focuses on improving photosynthesis, water capture, and crop efficiency, contributing to healthier and more flavorful food while reducing waste. Founded in 2012 and based in Emeryville, California, the company employs molecular discovery and life science approaches to create climate-resilient crops, ultimately enhancing productivity for farmers. Originally known as Asilomar Bio, Inc., it rebranded to Sound Agriculture Company in September 2018.

Opna Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics. The company focuses on creating new drugs that target the hallmarks of cancer, specifically addressing immune suppression mechanisms that facilitate the growth of cancer cells. By disrupting these processes, Opna Bio aims to provide physicians with more effective treatment options for cancer patients, enhancing the overall efficacy of cancer care.

EnPlusOne Biosciences specializes in developing innovative solutions for RNA therapeutics through its advanced synthesis platform. The company focuses on enzymatic-based RNA synthesis, which aims to address the limitations of traditional chemical synthesis methods. By tackling systemic challenges related to scaled production and access to novel therapeutic modifications, EnPlusOne enables the sustainable manufacturing of therapeutic RNA at a commercial scale. This approach positions the company to contribute significantly to the growing field of RNA-based therapeutics.

Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.

Vestaron Corporation specializes in the development, manufacture, and sale of peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T, Spear-Lep, and Leprotec, which target various pests in vegetables, fruits, and field crops. The company aims to enhance crop safety, efficacy, and sustainability by providing biopesticides that address resistance issues while ensuring safety for workers and the environment. Vestaron has received notable accolades for its innovative solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, recognizing its commitment to environmental stewardship and effective crop protection.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

Vestaron Corporation specializes in the development, manufacture, and sale of peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T, Spear-Lep, and Leprotec, which target various pests in vegetables, fruits, and field crops. The company aims to enhance crop safety, efficacy, and sustainability by providing biopesticides that address resistance issues while ensuring safety for workers and the environment. Vestaron has received notable accolades for its innovative solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, recognizing its commitment to environmental stewardship and effective crop protection.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Established in 2019 and headquartered in Waltham, Massachusetts, Eleanor Health offers comprehensive, whole-person care for mental health and substance misuse. Its services include evidence-based outpatient care, medication-assisted treatment for addiction, and personalized recovery plans, which are delivered through a network of outpatient clinics, virtually, and in community and home settings. This integrated approach aims to expedite the recovery process for individuals suffering from substance use disorders.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

OPT Industries is a digital manufacturing company founded in 2019 by Jifei Ou in Cambridge, Massachusetts. The company specializes in designing and mass-producing precision-engineered products at the micron scale, leveraging a combination of advanced machinery, software, and design expertise. OPT Industries offers its clients the ability to develop innovative product concepts and efficiently transition them to commercialization with rapid and scalable production capabilities. By providing high-quality products with shortened lead times, the company caters to globally recognized brands seeking to enhance their offerings through precision manufacturing solutions.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Story Health Corporation, founded in 2020 and based in Saratoga, California, develops advanced virtualized clinical care software tools aimed at aiding healthcare specialists, particularly neurologists and primary care physicians. The company offers a comprehensive healthcare technology platform that includes virtual patient programs, therapy management, and analytics designed to bridge the gap between clinical evidence and patient experiences. By utilizing data from high-frequency sources, Story Health empowers clinicians to better understand medical situations and make informed decisions regarding the physiological impacts of diseases and therapies. Through its innovative approach, Story Health enhances the ability of specialists to deliver effective patient care.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Walking Fish Therapeutics is focused on creating cell-based therapeutics that utilize the unique capabilities of B cells to activate the immune system for cancer treatment. The company is developing a platform that aims to function as in vivo protein factories, producing replacement proteins for deficiency diseases and engineered antibodies. By harnessing the power of locally acting proteins, Walking Fish Therapeutics seeks to address serious health conditions across oncology, regenerative medicine, and autoimmune diseases, ultimately enabling healthcare providers to concentrate on innovative therapeutic approaches in these fields.

QbDVision is a developer of a product life cycle management platform tailored for the biopharma sector. The platform offers a digital solution for managing development processes by consolidating data and knowledge from various teams into a single, searchable, cloud-based hub. It integrates product, process, and quality workflows, enhancing collaboration and minimizing inefficiencies associated with outdated software systems. This comprehensive approach allows organizations to maintain a historical perspective on their product and processes, facilitating better decision-making throughout the life cycle. Ultimately, QbDVision aims to increase the likelihood of technical success and expedite the delivery of therapeutic breakthroughs to patients.

1859, Inc. is a biotechnology company established in 2019 and headquartered in San Diego, California. It specializes in the discovery and development of next-generation therapeutics, utilizing an artificial intelligence-powered drug discovery platform. This innovative platform combines combinatorial chemistry and pico-scale activity-based screening to generate extensive empirical data. By harnessing these advanced technologies, the company aims to expedite the discovery of novel small molecule therapeutics, offering valuable solutions to pharmaceutical companies in the healthcare industry.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

64x Bio develops a platform aimed at accelerating the discovery and optimization of mammalian cell lines for biomanufacturing and therapeutics. The company employs a high-throughput discovery and screening approach combined with an integrated computational design loop to create genetically engineered cell lines tailored for the production of viral vectors. This focus is particularly relevant for cell and gene therapies, as it enhances the efficiency of viral vector production. By providing purpose-built cell lines, 64x Bio enables pharmaceutical and biotechnology companies to improve their manufacturing capacity and reduce costs, ultimately facilitating the timely delivery of innovative therapies to patients.

Ori Biotech is a developer of a manufacturing platform designed to enhance access to lifesaving treatments through cell and gene therapies. The company has created a proprietary and flexible manufacturing system that automates and standardizes the production process, facilitating the transition of therapeutics from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs for therapeutics developers. This innovative approach is intended to accelerate the commercialization of cell and gene therapies, ultimately providing patients with a new generation of personalized and effective treatments.

Scitara is a global provider of cloud-based software solutions tailored for laboratories in the life sciences and other science-focused sectors. The company specializes in developing a standardized platform that enhances communication and automates workflows within scientific environments. Its software facilitates platform deployment, validation, lab computing, and cloud integration, thereby empowering laboratories with modern data connectivity infrastructure. By offering tools that enable deeper insights into laboratory operations, Scitara supports the digital transformation of scientific laboratories, helping accelerate research and innovation.

Totus Medicines specializes in developing innovative therapies to address previously untreatable diseases by harnessing advanced chemical biology techniques. The company utilizes a proprietary platform that enables high-throughput drug discovery, allowing it to screen billions of drug candidates against thousands of biological targets. This approach focuses on identifying effective molecules for traditionally challenging and undruggable targets, including those associated with cancer, Alzheimer's, infectious diseases, and the aging process. By converting genetic insights into viable therapeutic options, Totus Medicines aims to make a significant impact on the treatment landscape for various complex diseases.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which combines cutting-edge simulation techniques with extensive experimental datasets. This technology allows researchers to examine the cancer microenvironment, gaining insights into tumor behavior, cell phenotypes, and interactions with surrounding tissues. By transforming comprehensive diagnostic datasets into personalized virtual tumors, SimBioSys enhances decision-making for healthcare providers and improves patient experiences in cancer treatment. Ultimately, the platform aims to facilitate a deeper understanding of cancer dynamics, enabling more effective and tailored therapeutic approaches.

Culture Biosciences, Inc. is a biomanufacturing company based in South San Francisco, California, that offers a cloud-based platform for scientists to conduct, monitor, and analyze bioreactor experiments. Founded in 2016, the company focuses on automating bioprocesses to help biotech firms optimize their manufacturing processes and expedite product development. By utilizing robotic sample handling and cloud data monitoring, Culture Biosciences enhances the efficiency of fermentation and bioreactor operations, allowing researchers to achieve results more rapidly than with traditional methods.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.

Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and farm revenues while addressing challenges such as drought. The company offers Source, a solution that enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby helping growers optimize crop performance sustainably. Additionally, Sound Agriculture focuses on improving photosynthesis, water capture, and crop efficiency, contributing to healthier and more flavorful food while reducing waste. Founded in 2012 and based in Emeryville, California, the company employs molecular discovery and life science approaches to create climate-resilient crops, ultimately enhancing productivity for farmers. Originally known as Asilomar Bio, Inc., it rebranded to Sound Agriculture Company in September 2018.

Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Hawthorne Effect is a clinical trial data platform committed to enhancing the accessibility and convenience of clinical trials for all individuals. It achieves this through a proactive Visit Management System that strengthens the partnership between study sponsors and investigators, leveraging shared technology to ensure adherence to protocols and reduce data omissions. The platform integrates licensed healthcare professionals with advanced connected technology, facilitating decentralized clinical trials that improve efficiency and accuracy compared to traditional methods. By deploying specially trained healthcare providers, known as “HEROs,” Hawthorne Effect allows for patient visits to be conducted anywhere and at any time, thereby minimizing the risk of patients being lost to follow-up and ensuring comprehensive tracking of patient data.

Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.

Torus Biosystems, founded in 2019 and based in Cambridge, Massachusetts, develops a diagnostic device that enables DNA testing for scientific and medical research. The company's apparatus is designed for various applications, including consumer products, food safety for humans and animals, and sectors such as hygiene, beauty care, agriculture, horticulture, and forestry. By providing access to DNA testing for non-medical purposes, Torus Biosystems supports the advancement of research across multiple fields.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

Outcomes4Me Inc. is an AI-driven healthcare platform based in Cambridge, Massachusetts, founded in 2017. It focuses on empowering cancer patients by providing access to personalized, evidence-based treatment options and clinical information. The platform enables patients to navigate their care proactively, facilitating informed decision-making and improving health outcomes. By democratizing healthcare, Outcomes4Me promotes health equity and supports deeper insights into patient care, while also accelerating research and access to innovative treatments. The company is led by a team of experienced professionals from various sectors, including healthcare, oncology, and technology, dedicated to enhancing the patient experience in cancer treatment.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.

VieCure is a provider of an advanced artificial intelligence platform designed to enhance cancer care by transforming data into actionable insights. The platform enables oncologists to develop personalized treatment plans that are tailored to each patient's unique needs, drawing on the latest evidence-based knowledge and genomic guidelines. By codifying premier cancer information, VieCure supports clinicians in creating comprehensive care strategies that align with nationally accepted standards. This innovative approach not only aids healthcare professionals in delivering high-quality care but also empowers patients to actively engage in their treatment journey, ultimately helping them to live their best lives.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, established in 2015. The company focuses on developing innovative adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Utilizing a proprietary platform that combines structural insights with accelerated evolution, StrideBio creates novel AAV capsids designed to evade neutralizing antibodies. This approach allows for enhanced gene addition, gene silencing, and gene editing capabilities, addressing the limitations of first-generation gene therapies. By engineering unique and differentiated vectors, StrideBio aims to improve treatment outcomes for patients facing devastating conditions.

Vestaron Corporation specializes in the development, manufacture, and sale of peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T, Spear-Lep, and Leprotec, which target various pests in vegetables, fruits, and field crops. The company aims to enhance crop safety, efficacy, and sustainability by providing biopesticides that address resistance issues while ensuring safety for workers and the environment. Vestaron has received notable accolades for its innovative solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, recognizing its commitment to environmental stewardship and effective crop protection.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Scitara is a global provider of cloud-based software solutions tailored for laboratories in the life sciences and other science-focused sectors. The company specializes in developing a standardized platform that enhances communication and automates workflows within scientific environments. Its software facilitates platform deployment, validation, lab computing, and cloud integration, thereby empowering laboratories with modern data connectivity infrastructure. By offering tools that enable deeper insights into laboratory operations, Scitara supports the digital transformation of scientific laboratories, helping accelerate research and innovation.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

NanoView Biosciences is a biotechnology company that specializes in the development of technologies for the characterization of extracellular vesicles, particularly exosomes. Founded in 2015 and based in Boston, Massachusetts, the company utilizes its proprietary ExoView technology to provide high-throughput and cost-effective analysis solutions for life science researchers. NanoView's products, which include the ExoView R100 and ExoView tetraspanin, enable precise detection and multiparametric characterization of exosomes from complex biological samples such as blood, serum, plasma, and urine. In addition to its core products, the company offers custom assays, sample services, and a support platform to aid researchers in understanding the biological roles of exosomes and utilizing them as biomarkers for disease diagnosis, treatment, and monitoring.

Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.

General Automation Lab Technologies, Inc. specializes in developing and commercializing microbiological technologies that enhance the study of bacteria and other microbes. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed for microbial research. This platform enables scientists to access a diverse range of microbes and isolate rare or unique species, facilitating deeper insights into their functions. The applications of its microbe systems span various fields, including agriculture, human health, environmental science, and industrial processes. Established in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and aims to advance microbiome science through innovative technologies.

ArtisanBio is a company that specializes in cell engineering and data analysis solutions aimed at enhancing cell therapies. Its platform allows partners to optimize candidate designs, facilitating the development of safer and more effective cellular therapies for various human health conditions. By focusing on rapid discovery, editing performance, and data analytics, ArtisanBio addresses the complexities of next-generation cell therapies. The company actively collaborates with innovative partners to deliver customizable solutions, advancing the overall effectiveness of therapeutic applications in the healthcare sector.

Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry technology for the analysis of biomolecules. The company's flagship product, Refeyn One, employs single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. This innovative optical technology allows researchers to measure the mass of individual molecules in their native state without the necessity for labels, providing both quality-control instruments and advanced research tools. Refeyn's offerings enable scientists to conduct mass measurements across a range of biologically relevant concentrations, enhancing the capabilities of biomolecular analysis.

Ori Biotech is a developer of a manufacturing platform designed to enhance access to lifesaving treatments through cell and gene therapies. The company has created a proprietary and flexible manufacturing system that automates and standardizes the production process, facilitating the transition of therapeutics from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs for therapeutics developers. This innovative approach is intended to accelerate the commercialization of cell and gene therapies, ultimately providing patients with a new generation of personalized and effective treatments.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.

Intabio, Inc. is a biopharmaceutical analytics company founded in 2015 and based in Newark, California. The company specializes in developing innovative analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing. Intabio's key product, the Blaze system, is a bench-top instrument that utilizes a microfluidic chip and reagent kit to perform separation, quantitation, and molecular mass identity analysis. This system is particularly valuable for identifying unwanted structural modifications in intact biotherapeutic proteins. Intabio also offers a microfluidic platform that enables real-time characterization of protein isoforms, aiding in the identification of specific modifications. By providing early product quality characterization, Intabio's technologies significantly improve throughput and reduce costs compared to traditional methods, facilitating the comprehensive analysis of antibody and protein biopharmaceuticals in development.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

IsoPlexis is a life science technology company based in Branford, Connecticut, founded in 2013. It focuses on developing a single-cell detection system that identifies patient immune responses at the single-cell level. This innovative platform enables the assessment of therapeutic safety and efficacy, as well as the monitoring of disease progression. IsoPlexis specializes in cell-based proteomic systems and biomarkers, providing insights into functional protein biology and cellular signaling networks with high resolution. By offering these capabilities, the company aids in predicting patient responses to novel immunotherapies and cellular therapies, ultimately enhancing therapeutic development and informing clinical decisions.

IsoPlexis is a life science technology company based in Branford, Connecticut, founded in 2013. It focuses on developing a single-cell detection system that identifies patient immune responses at the single-cell level. This innovative platform enables the assessment of therapeutic safety and efficacy, as well as the monitoring of disease progression. IsoPlexis specializes in cell-based proteomic systems and biomarkers, providing insights into functional protein biology and cellular signaling networks with high resolution. By offering these capabilities, the company aids in predicting patient responses to novel immunotherapies and cellular therapies, ultimately enhancing therapeutic development and informing clinical decisions.